TY - JOUR
T1 - Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer
AU - Auclin, Edouard
AU - Benitez-Montanez, Jose
AU - Tagliamento, Marco
AU - Parisi, Francesca
AU - Gorria, Teresa
AU - Garcia-Campelo, Rosario
AU - Dempsey, Naomi
AU - Pinato, David J.
AU - Reyes, Roxana
AU - Albarran-Artahona, Victor
AU - Dall'Olio, Filippo
AU - Soldato, Davide
AU - Hendriks, Lizza
AU - Nana, Frank Aboubakar
AU - Tonneau, Marion
AU - Lopez-Castro, Rafael
AU - Nadal, Ernest
AU - Kazandjian, Suzanne
AU - Muanza, Thierry
AU - Blanc-Durand, Felix
AU - Fabre, Elizabeth
AU - Castro, Natalia
AU - Arasanz, Hugo
AU - Rochand, Adrien
AU - Besse, Benjamin
AU - Routy, Bertrand
AU - Mezquita, Laura
PY - 2023/4/1
Y1 - 2023/4/1
N2 - Introduction: Chemotherapy plus immunotherapy is the standard of care for patients with metastatic NSCLC. No study has evaluated the outcomes of second-line chemotherapy treatments after progression following first-line chemo-immunotherapy. Method: This multicenter retrospective study evaluated the efficacy of second line (2L) chemotherapies after progression under first-line (1L) chemo-immunotherapy, measured by overall survival (2L-OS) and progression free survival (2L-PFS). Results: A total of 124 patients were included. The mean age was 63.1 years, 30.6 % of the patients were female, 72.6 % had an adenocarcinoma and 43.5 % had a poor ECOG-performance status prior to 2L initiation. Sixty-four (52.0 %) patients were considered resistant to first line chemo-immunotherapy. (1L-PFS < 6 months). In 2L treatments, 57 (46.0 %) patients received taxane monotherapy, 25 (20.1 %) taxane plus anti-angiogenic, 12 (9.7 %) platinum-based chemotherapy and 30 (24.2 %) other chemotherapy.
AB - Introduction: Chemotherapy plus immunotherapy is the standard of care for patients with metastatic NSCLC. No study has evaluated the outcomes of second-line chemotherapy treatments after progression following first-line chemo-immunotherapy. Method: This multicenter retrospective study evaluated the efficacy of second line (2L) chemotherapies after progression under first-line (1L) chemo-immunotherapy, measured by overall survival (2L-OS) and progression free survival (2L-PFS). Results: A total of 124 patients were included. The mean age was 63.1 years, 30.6 % of the patients were female, 72.6 % had an adenocarcinoma and 43.5 % had a poor ECOG-performance status prior to 2L initiation. Sixty-four (52.0 %) patients were considered resistant to first line chemo-immunotherapy. (1L-PFS < 6 months). In 2L treatments, 57 (46.0 %) patients received taxane monotherapy, 25 (20.1 %) taxane plus anti-angiogenic, 12 (9.7 %) platinum-based chemotherapy and 30 (24.2 %) other chemotherapy.
KW - Non small cell lung cancer
KW - Chemo-immunotherapy
KW - Second line
KW - Prognosis
KW - Survival
KW - DOCETAXEL
KW - NIVOLUMAB
U2 - 10.1016/j.lungcan.2023.02.002
DO - 10.1016/j.lungcan.2023.02.002
M3 - Article
C2 - 36812760
SN - 0169-5002
VL - 178
SP - 116
EP - 122
JO - Lung Cancer
JF - Lung Cancer
IS - 1
ER -